M. Tabrizizad

Structural basis for the activity of drugs that inhibit phosphodiesterases.

Kam Y. J. Zhang, Sung-Hou Kim, M. Milburn, 2004, Structure.

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Z. An, M. Tabrizizad, A. Lucas, 2021, Journal for ImmunoTherapy of Cancer.

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Ben J. Powell, Yoshihisa Suzuki, J. Tsai, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

M. Lilly, Chao Zhang, M. Tabrizizad, 2007, Molecular Cancer Therapeutics.

The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.

M. Milburn, K. Eng, Ben J. Powell, 2005, Proceedings of the National Academy of Sciences of the United States of America.

198 Innate-enhanced chimeric adaptors (CAd): A newly-described approach for augmenting potency of γδ T cell immunotherapy

M. Tabrizizad, Gauri Lamture, B. Aftab, 2022, Regular and Young Investigator Award Abstracts.

119 ADI-002: an IL-15 armored allogeneic ‘off-the-shelf’ Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)

A. Lucas, Z. An, M. Tabrizizad, 2021, Journal for ImmunoTherapy of Cancer.